Is Jubilant Ingrev. overvalued or undervalued?

As of 16 June 2025, the valuation grade for Jubilant Ingrev. has moved from expensive to fair, indicating a shift in its market perception. The company is currently fairly valued, with a PE ratio of 48.80, an EV to EBITDA of 24.87, and a PEG ratio of 1.31. In comparison, peers such as Sun Pharma. Inds. and Cipla have PE ratios of 35.37 and 23.39, respectively, showcasing that Jubilant Ingrev. is positioned higher in terms of valuation metrics.
Despite its relatively high valuation ratios, Jubilant Ingrev. has shown strong performance, particularly over the past year with a stock return of 51.66%, significantly outpacing the Sensex return of 6.24%. This performance, combined with its fair valuation status, suggests that while the company is not undervalued, it remains a strong player in the specialty chemicals sector.